| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
| ln Vitro |
With IC50 values of 1.1 ± 0.2 μM and 1.3 ± 0.2 μM, respectively, BD750 inhibits the proliferation of human T cells stimulated by anti-CD3/anti-CD28 mAb or alloantigen in a dose-dependent manner [1]. Additionally, BD750 prevents the proliferation of human T cells induced by PMA/ionomycine or PHA, as well as that of mouse T cells induced by ConA, PMA/ionomycine, or alloantigens [1]. BD750 (5 or 20 μM) inhibits LPS-induced JAK-STAT5 signaling in DCs [2].
|
|---|---|
| ln Vivo |
BD750 can promote tolerance dendritic cells (tolDC) and their function in experimental autoimmune encephalitis (EAE) in mice [2].
|
| Cell Assay |
Western blot analysis[2]
Cell Types: purified immature DC. Tested Concentrations: 1, 5 or 20 μM. Incubation Duration: 12 hrs (hours). Experimental Results: Fewer small dendrites and smaller clusters compared to typical mDC (5 or 20 μM). Higher doses Dramatically diminished the levels of IL-6, IL-12, TNF-α, IL-1β, and IL-23 produced by LPS-stimulated DCs. |
| Animal Protocol |
Animal/Disease Models: Female C57BL/6 mice (10 weeks old, 19-21 g) [2].
Doses: 20μM. Route of Administration: IV, process DC on days 7, 11 and 15 after first PTX injection (dpi 7, 11 and 15). Experimental Results: The frequency of Th1 and Th17 cells was Dramatically diminished and the percentage of Treg cells was increased compared to mice receiving PBS. |
| References |
|
| Molecular Formula |
C14H13N3OS
|
|---|---|
| Molecular Weight |
271.337521314621
|
| Exact Mass |
271.077
|
| CAS # |
892686-59-8
|
| PubChem CID |
16459674
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
3.5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
19
|
| Complexity |
436
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC1N(C2SC3C(=CC=CC=3)N=2)N=C2CCCCC=12
|
| InChi Key |
QWUHPPCZZXKXOQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H13N3OS/c18-13-9-5-1-2-6-10(9)16-17(13)14-15-11-7-3-4-8-12(11)19-14/h3-4,7-8,16H,1-2,5-6H2
|
| Chemical Name |
2-(1,3-benzothiazol-2-yl)-4,5,6,7-tetrahydro-1H-indazol-3-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~460.68 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.67 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6854 mL | 18.4271 mL | 36.8541 mL | |
| 5 mM | 0.7371 mL | 3.6854 mL | 7.3708 mL | |
| 10 mM | 0.3685 mL | 1.8427 mL | 3.6854 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
